Skip to content
Menu
Breaking Efficacy Ceilings
Home
About
Science
Pipeline
News
Careers
Triveni Bio
News
The latest company updates, news, and insights
Triveni Bio Doses First Patient in Global Phase 2 Proof-of-Concept Study of TRIV-573 in Atopic Dermatitis and Provides I&I Pipeline Update
Press Release
10.13.2026
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Press Release
6.17.2026
Top
